Labcorp Enhances Oncology Portfolio to Transform Cancer Patient Care and Research
Labcorp Enhances Oncology Portfolio to Transform Cancer Patient Care and Research
Labcorp, a leading provider of laboratory services globally, has unveiled significant enhancements to its oncology portfolio, aimed at improving the quality of care for cancer patients and accelerating research advancements. This expansion centers on new testing capabilities for solid tumors and hematologic malignancies, as well as enhanced biopharma services that aid in clinical trials and companion diagnostic development.
Commitment to Patient Care and Research
Dr. Shakti Ramkissoon, Labcorp's Vice President and Medical Lead for Oncology, emphasized the company's dedication to being a reliable partner for advanced cancer testing at all care stages. The newly expanded offerings are designed to provide essential tools and insights that empower healthcare professionals to expedite development programs and ultimately improve patient outcomes.
New Testing Solutions for Cancer Diagnosis
Labcorp's new tests will significantly enhance patient access and treatment personalization. Key advancements include:
- - Next-Generation Sequencing (NGS) Panels: New panels focused on myeloid, lymphoid, and pan-heme indications will offer wider genomic coverage and actionable insights for hematologic cancers. This will aid oncologists and pathologists in making faster, clearer decisions.
- - Rapid AML Panel: This addition to Labcorp's testing menu for acute myeloid leukemia will support timely and informed treatment options for patients, crucial in such a rapidly changing field.
- - OmniSeq® INSIGHT Enhancements: This pan-solid tumor profiling test is set to include homologous recombination deficiency (HRD) testing, helping to identify ovarian cancer patients who might benefit most from targeted therapies or clinical trial options.
- - FDA-Approved Companion Diagnostics: New categorizations for breast cancer subtypes and a new test for non-squamous non-small cell lung cancer showcase Labcorp's commitment to personalized medicine and improved treatment efficacy.
- - Digital Pathology Advancements: Efforts to enhance anatomic pathology capabilities with further updates on the horizon for 2025.
Strengthening Biopharma Laboratory Services
In its mission to improve clinical trial outcomes, Labcorp is also broadening its biopharma services. Notable initiatives include:
- - Global Expansion of Labcorp Plasma Focus™: This liquid biopsy test designed for solid tumors will now be available through Labcorp's centers in Geneva, Switzerland, and Shanghai, China, ensuring more consistent testing standards across different regions.
- - Digital Pathology for Clinical Trials: Labcorp is harnessing advanced digital pathology technologies, such as Leica Biosystems Aperio GT450 scanners and Proscia's Concentriq LS, to enhance workflow and deliver real-time global peer reviews, facilitating better and faster diagnostic collaboration.
Upcoming Presentation at ASCO 2025
Labcorp is poised to share its latest research findings at the upcoming ASCO® Annual Meeting scheduled from May 30 to June 3 in Chicago. Discussions will center around enhancements in oncology solutions that reflect the company’s ongoing commitment to transforming cancer care.
For more details on Labcorp’s oncology initiatives or to explore their solutions for healthcare professionals, visit their Oncology Solutions Page.
About Labcorp
Labcorp (NYSE: LH) is an innovator in laboratory services, assisting healthcare providers in making clear and informed decisions. With nearly 70,000 employees globally, Labcorp supports a vast array of clients while contributing to over 75% of new drug approvals by the FDA, underscoring its pivotal role in improving healthcare outcomes worldwide. For further information, visit Labcorp's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.